Skip to main content
Alnylam Makes Rare Disease Education Accessible to Kids with Animated Videos
Alnylam Pharmaceuticals has blended a children’s cartoon with a disease awareness campaign in its latest education effort for pediatric rare disease PH1. Kids with PH1, or primary hyperoxaluria type 1, often need special accommodations at school. Because PH1 affects the kidneys and liver and causes recurring kidney stones, children with this rare disease need to drink a lot of water and must leave class often to go to the bathroom or get water.
Mid-stage Data on Allena's Hyperoxaluria Drug Fuel Optimism Ahead of Pivotal Readout
Ahead of the pivotal data of its lead experimental drug for hyperoxaluria, Allena Pharmaceuticals revealed interim data from a small mid-stage study on Wednesday, that signaled the drug confers benefits in certain patients with advanced chronic kidney disease (CKD) that are at risk of systemic oxalosis, a potentially life-threatening condition.
New Clinical Study Shows Promise for Dietary Management of Hyperoxaluria
Results from Captozyme, Inc.’s post-market study of an innovative enzyme to support kidney health have been accepted for poster presentation on May 4 at the American Urological Association (AUA) Annual Meeting in Chicago.
Invitae, Alnylam to Provide Free Genetic Testing for Primary Hyperoxaluria
Invitae announced today that it is partnering with RNAi therapeutics firm Alnylam Pharmaceuticals to provide free genetic testing to improve diagnosis and management of a rare inherited disorder called primary hyperoxaluria.
Hyperoxaluria and oxalosis care at Mayo Clinic
The Mayo Clinic Hyperoxaluria Center in Minnesota brings together doctors from many specialties to design a personalized treatment plan, based on the type and severity of hyperoxaluria and any related conditions. Mayo Clinic coordinates your testing and doctor appointments to speed the process of diagnosis and treatment. A specialist in kidney diseases (nephrologist) usually manages your care.